Assessing Left Ventricular Remodeling via Temporal Detection and Measurement of microRNA in Body Fluids

Description:

This invention provides a method of assessing cardiac disease including thoracic aortic aneurysm (TAA) and left ventricular (LV) remodeling by measuring the levels of 5 microRNAs (miRs) in a body fluid such as plasma or serum, or in cardiac and aortic tissue. miRs are small noncoding RNAs that recognize and bind to mRNA and inhibit protein translation or degrade mRNA. This method allows for the assessment of the risk, development, presence, severity, or a combination, of TAA in the subject. In a separate assay, clinicians can assess the presence and/or severity of LV remodeling post ischemia-reperfusion. The miRs levels can be measured by performing a simple blood test. This simple and efficient method can potentially make prognoses more efficient and economical compared to current methods.

Overview:
Thoracic aneurysms affect approximately 15,000 people in the United States each year, and this number is expected rise with the aging "Baby Boomer" generation. Aneurysms develop gradually over many years, and most patients have no symptoms until the aneurysm begins to leak or expand. The survival rate of hospitalized patients with a ruptured TAA is usually less than 20 to 30 percent. Annual surveillance methods, including CT scanning and MRI studies pose additional risks to patients or are not widely accessible due to high cost. There is a growing, unmet need for early diagnosis of patients with TAA, as this can improve patient outcomes resulting in reduced cost for hospitals, a reduction in mortality rate among TAA patients, and increased patient access.

Worldwide, more than seven million people die due to coronary heart disease each year. Following presentation of myocardial infarction, a left ventricular (LV) remodeling process occurs in patients. The rate and extent of this post-MI remodeling process has been established to be independent predictors of morbidity and mortality. The current method for assessing the remodeling is the use of electrocardiogram which is a costly diagnostic tool. There is a growing need for a more rapid and cost-effective means of diagnosis and tracking of the LV remodeling process in a patient. Measuring miRs following a myocardial infarction may prove to be a more cost-effective means to monitoring the LV remodeling process in patients.

Advantages: Early identification and monitoring of patients at risk for thoracic aortic aneurysm; Rapid and cost-effective assessment of the presence and/or severity of LV remodeling

Key Words: Hypertrophic heart failure, thoracic aortic aneurysm (TAA), microRNA, congestive heart failure - CHF, heart failure with reduced ejection fraction – HFrEF, myocardial infarction, left ventricular remodeling, hypertension, obesity, diabetes

Publications: Jones, Jeffrey A., et al. "Selective MicroRNA Suppression in Human Thoracic Aneurysms Relationship of miR-29a to Aortic Size and Proteolytic Induction."Circulation: Cardiovascular Genetics 4.6 (2011): 605-613.

Inventors: F.G. Spinale, M.R. Zile, R.E. Stroud
Patent Status: US Patent 8,592,151
MUSC-FRD Technology ID:
P1001

Patent Information:
Category(s):
Diagnostic
For Information, Contact:
Mark Hankins
Director of Licensing
MUSC Foundation for Research Development
hankinsm@musc.edu
Inventors:
Francis Spinale
Michael Zile
Robert Stroud
Keywords:
cardiovascular
diagnostic
© 2017. All Rights Reserved. Powered by Inteum